Author: [AUTHOR] Published on 8/1/2020 12:00:00 AM
Chao Chen, PhD, Senior Director, GlaxoSmithKline, London, England
ASCPT is widely recognized as the top organization that brings together drug developers, academic researchers, regulators, and research clinicians toward the common goals of enhancing the efficiency of drug development and approval, and optimizing pharmacotherapies for individual patients on balance of efficacy and safety. It is a rich environment in which to exchange ideas, facilitate collaboration, and develop new scientists. These drew Dr. Chen to join the Society. As a member, he hopes to connect to colleagues from the diverse background that attracted him. He believes that being a member will open the door to better access to a collection of valuable resources. He specifies the ASCPT journal family as a source of a broad scope of knowledge and a strong source of inspiration. He also looks forward to taking part in the Annual Meeting and webinars.
As a career drug developer specializing in quantitative clinical pharmacology, Dr. Chen is most interested in translational pharmacology modeling, simulation‐assisted design of clinical trials, understanding the dose–response relationship in the course of diseases, and individualized treatment regimen. A common thread in all these activities is a framework to integrate the otherwise fragmented data, to make the best use of the existing information, to quantify the strength of understanding, and to identify key knowledge gaps. All these things are important for informing confident decisions in drug development and approval effectively and in a timely manner so that the limited public–private resources can be optimally deployed.
Dr. Chen impacts patient care in that he works to better understand the drug target in relation to the disease mechanism and unmet medical needs. He works to improve understanding on the levels of overall patient population, the subgroups, and the individuals. The earlier stages of medicine discovery and development are important for having a clear line of sight that guides the design of the clinical development and registration pathways for achieving the most successful treatment recommendations.